Skip to content

Study on the 18F-AV-1451 PET Image Change in Normal Subjects and Patients with Impaired Cognitive Function

Study on the 18F-AV-1451 PET Image Change in Normal Subjects and Patients with Brain Disease with Impaired Cognitive Function

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004331
Enrollment
380
Registered
2019-10-16
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Korea Cancer Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: cognitively normal participants: 1. A patient or guardian complains of cognitive impairment 2. Neuropsychological test confirmed that cognitive ability is lower than age and education 3. Maintain overall cognitive function 4. No problem in daily life 5. Should not be dementia at the discretion of the clinician. 6. The classification of Alzheimer's and Vascular Mild Cognitive Impairment is based on grade 3 of Fazekas criteria for white matter hyperintensities (WMH). vascaular MCI: 1. A patient or guardian complains of cognitive impairment 2. Neuropsychological test confirmed that cognitive ability is lower than age and education 3. Maintain overall cognitive function 4. No problem in daily life 5. Should not be dementia at the discretion of the clinician. 6. The classification of Alzheimer's and Vascular Mild Cognitive Impairment is based on grade 3 of Fazekas criteria for white matter hyperintensities (WMH). Alzheimer disease dementia; AD: 1. A person diagnosed with Probable Alzheimer's disorder based on NINCDS-ADRDA Alzheimer's Criteria 2. People positive for Major or Mild Neurocognitive Disorder due to Alzheimer ’s disease based on DSM-V-TR (Diagnostic and statistical manual of mental disorders, 5th) Vascular dementia; VaD: Applicable to the probably vascular dementia of the NINDS-AIREN criteria. Cerebral amyloid angiopathy; CAA: Have been clinically and imaging diagnosed according to the Modified Boston criteria; If the subject is 55 years of age or older and have a single bleeding or cortical superficial stenosis (CSS) without any other cause, possible CAAs.

Exclusion criteria

Exclusion criteria: 1. Persons found by the tester to be difficult to carry out research due to serious internal diseases; 2. A person who is judged by a tester to have a mental illness that is difficult to take PET photos 3. Persons who undergo heart surgery or have been diagnosed with myocardial infarction within six months of screening 4. Those who have received radiation for diagnostic or therapeutic purposes within 7 days of screening 5. Unregulated Diabetes 6. Premenopausal women who are pregnant, nursing, planning to conceive or not using recognized contraceptives during the study period. 7. Other persons deemed unfit by the Tester to participate in this study *In addition to the above exclusion criteria, the subjects to be registered at the KIRAMS to conduct eye examination are excluded from the subjects if: 1.a history of infection of the central nerve, or of surgery or brain tumors 2. A history of Parkinson's disease or multiple sclerosis. 3. History of diabetic retinopathy or hypertensive retinopathy 4. The history of retinal surgery 5. In case of history or retinal abnormalities that may affect the thickness of the retina nerve fiber layer 6. In case the characteristics of glaucoma are clearly visible or diagnosed as glaucoma; 7. In case of difficulty in watching housekeeping due to cataracts or confusion of medium 8. Anticipating pressure rise due to right angle closure is expected when an operation is attempted.

Design outcomes

Primary

MeasureTime frame
Rate of change in the brain region 18F-AV-1451 SUV for 4.5 years in each group

Secondary

MeasureTime frame
Pearson correlation coefficient between the change rate of the 18F-AV-1451 SUV and the thickness of the retinal nerve layer around the temporal larynx;Pearson correlation coefficient between the rate of change in brain region 18F-AV-1451 SUV and the rate of change in posterior parietal nerve cells-internal upper layer thickness;Pearson correlation coefficient between the change rate of the 18F-AV-1451 SUV in the brain region and the change rate of the volume of the imperial hemisphere;In the early stages of the brain region (0-10 minutes post injection) 18F-AV-1451 SUV rate of change

Countries

Korea, Republic of

Contacts

Public ContactByeonghyeon Byeon

Korea Cancer Center Hospital

nmbbh@kirams.re.kr+82-2-970-2241

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026